
Neogen Chemicals (NEOGEN) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
2.0B
Gross Profit
953.2M
47.00%
Operating Income
296.2M
14.60%
Net Income
24.1M
1.19%
Balance Sheet Metrics
Total Assets
17.5B
Total Liabilities
9.6B
Shareholders Equity
7.9B
Debt to Equity
1.21
Cash Flow Metrics
Operating Cash Flow
113.1M
Free Cash Flow
-3.7M
Revenue & Profitability Trend
Neogen Chemicals Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 7.8B | 6.3B | 6.6B | 4.7B | 3.4B |
Cost of Goods Sold | 4.2B | 4.0B | 4.1B | 3.1B | 2.4B |
Gross Profit | 3.5B | 2.3B | 2.5B | 1.7B | 969.8M |
Gross Margin % | 45.6% | 36.1% | 38.4% | 34.8% | 28.8% |
Operating Expenses | |||||
Research & Development | - | 34.9M | 47.0M | 47.0M | - |
Selling, General & Administrative | - | 304.6M | 307.4M | 162.4M | 128.4M |
Other Operating Expenses | 1.5B | 601.1M | 702.2M | 298.4M | 170.0M |
Total Operating Expenses | 1.5B | 940.6M | 1.1B | 507.8M | 298.4M |
Operating Income | 1.1B | 871.8M | 954.2M | 749.0M | 571.7M |
Operating Margin % | 14.0% | 13.8% | 14.4% | 15.8% | 17.0% |
Non-Operating Items | |||||
Interest Income | - | 74.1M | 38.3M | 6.0M | 1.3M |
Interest Expense | 485.0M | 377.8M | 237.0M | 178.0M | 129.3M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 501.6M | 527.7M | 710.3M | 570.7M | 442.1M |
Income Tax | 153.3M | 171.2M | 210.6M | 124.4M | 128.8M |
Effective Tax Rate % | 30.6% | 32.4% | 29.6% | 21.8% | 29.1% |
Net Income | 348.3M | 356.5M | 499.7M | 446.3M | 313.3M |
Net Margin % | 4.5% | 5.6% | 7.6% | 9.4% | 9.3% |
Key Metrics | |||||
EBITDA | 1.4B | 1.1B | 1.1B | 861.7M | 640.4M |
EPS (Basic) | ₹13.20 | ₹13.96 | ₹20.03 | ₹18.70 | ₹13.43 |
EPS (Diluted) | ₹13.20 | ₹13.96 | ₹20.03 | ₹18.70 | ₹13.43 |
Basic Shares Outstanding | 26386364 | 25540299 | 24939316 | 24939316 | 23334606 |
Diluted Shares Outstanding | 26386364 | 25540299 | 24939316 | 24939316 | 23334606 |
Income Statement Trend
Neogen Chemicals Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 49.6M | 122.3M | 182.2M | 328.0M | 5.1M |
Short-term Investments | 4.4B | 2.6M | 785.4M | 807.6M | 256.6M |
Accounts Receivable | 2.0B | 2.8B | 1.8B | 1.1B | 785.5M |
Inventory | 3.1B | 3.8B | 2.9B | 1.9B | 1.1B |
Other Current Assets | 440.8M | 365.3M | -100.0K | 219.2M | 1.0K |
Total Current Assets | 10.0B | 7.8B | 6.6B | 4.9B | 2.4B |
Non-Current Assets | |||||
Property, Plant & Equipment | 4.0B | 660.6M | 483.3M | 384.8M | 220.9M |
Goodwill | 9.4M | 11.5M | 14.1M | 1.6M | 3.3M |
Intangible Assets | - | 11.5M | 14.1M | 1.6M | 3.3M |
Long-term Investments | - | 0 | 0 | - | - |
Other Non-Current Assets | 1.7B | -200.0K | -100.0K | -100.0K | -100.0K |
Total Non-Current Assets | 7.5B | 6.8B | 4.0B | 3.1B | 2.5B |
Total Assets | 17.5B | 14.6B | 10.5B | 8.0B | 4.9B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 2.6B | 1.4B | 1.6B | 988.8M | 660.8M |
Short-term Debt | 4.0B | 2.7B | 2.4B | 1.1B | 1.0B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 204.1M | 56.9M | 15.4M | 22.0M | 18.0M |
Total Current Liabilities | 7.3B | 5.3B | 4.1B | 2.2B | 1.8B |
Non-Current Liabilities | |||||
Long-term Debt | 1.9B | 1.4B | 1.3B | 1.2B | 1.2B |
Deferred Tax Liabilities | 174.1M | 237.3M | 190.2M | 106.1M | 81.6M |
Other Non-Current Liabilities | - | 100.0K | -900.0K | -800.0K | -100.0K |
Total Non-Current Liabilities | 2.2B | 1.7B | 1.6B | 1.4B | 1.3B |
Total Liabilities | 9.6B | 7.0B | 5.7B | 3.6B | 3.1B |
Equity | |||||
Common Stock | 263.8M | 263.8M | 249.4M | 249.4M | 233.3M |
Retained Earnings | - | 2.0B | 1.7B | 1.3B | 881.7M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 7.9B | 7.6B | 4.8B | 4.4B | 1.8B |
Key Metrics | |||||
Total Debt | 6.0B | 4.1B | 3.7B | 2.3B | 2.2B |
Working Capital | 2.7B | 2.6B | 2.5B | 2.7B | 622.2M |
Balance Sheet Composition
Neogen Chemicals Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 501.6M | 527.7M | 710.3M | 570.7M | 442.1M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -485.0M | -1.2B | -1.9B | -1.1B | -3.0M |
Operating Cash Flow | 645.5M | -230.4M | -891.3M | -337.9M | 576.8M |
Investing Activities | |||||
Capital Expenditures | -3.2B | -3.0B | -1.0B | -661.3M | -1.4B |
Acquisitions | 0 | 35.2M | 0 | - | - |
Investment Purchases | - | - | - | -807.6M | 0 |
Investment Sales | - | 0 | 47.0M | - | - |
Investing Cash Flow | -3.2B | -3.0B | -940.4M | -1.5B | -1.4B |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -52.8M | -74.8M | -68.6M | -52.5M | -46.7M |
Debt Issuance | 2.4B | 666.2M | 2.3B | 388.8M | 978.4M |
Debt Repayment | -718.0M | -352.9M | -899.9M | -430.4M | -282.4M |
Financing Cash Flow | 1.7B | 2.7B | 1.3B | 2.1B | 645.0M |
Free Cash Flow | -1.2B | -3.3B | -1.3B | -1.7B | -514.7M |
Net Change in Cash | -854.1M | -517.8M | -539.4M | 342.8M | -128.4M |
Cash Flow Trend
Neogen Chemicals Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
111.20
Forward P/E
44.29
Price to Book
4.76
Price to Sales
4.78
PEG Ratio
44.29
Profitability Ratios
Profit Margin
4.29%
Operating Margin
13.78%
Return on Equity
4.41%
Return on Assets
1.99%
Financial Health
Current Ratio
1.36
Debt to Equity
75.60
Beta
-0.08
Per Share Data
EPS (TTM)
₹12.77
Book Value per Share
₹298.07
Revenue per Share
₹297.23
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
neogen | 37.5B | 111.20 | 4.76 | 4.41% | 4.29% | 75.60 |
Asian Paints | 2.4T | 65.80 | 12.24 | 18.28% | 10.63% | 11.42 |
Pidilite Industries | 1.6T | 71.77 | 16.03 | 20.85% | 16.16% | 4.56 |
Balaji Amines | 49.7B | 32.59 | 2.69 | 7.80% | 11.11% | 0.55 |
Camlin Fine Sciences | 44.0B | 81.82 | 4.88 | 5.71% | -8.34% | 77.88 |
Grauer & Weil | 43.7B | 27.77 | 4.65 | 18.02% | 13.85% | 1.26 |
Financial data is updated regularly. All figures are in the company's reporting currency.